ophthalmology

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

News

Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.

News

In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.

News

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

News

Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.